. 2021 May 16;191:105089. doi: 10.1016/j.antiviral.2021.105089

Table 2.

Antiviral efficacy, measured by a reduction in mean infectious virus (Log₁₀ pfu/mL), and selectivity of astodrimer sodium against SARS-CoV-2 (2019-nCoV/USA-WA1/2020) on Day 4 post-infection.

Compound/Assay Type	Cell Line	EC₅₀ (mg/mL)	CC₅₀ (mg/mL)	SI
Astodrimer sodium added 1-h pre-infection	Vero E6	0.032	15.09	472
Astodrimer sodium added 1-h pre-infection	Calu-3	0.037	21.76	588
Astodrimer sodium added at time of infection	Vero E6	0.020	15.09	755
Astodrimer sodium added at time of infection	Calu-3	0.035	21.76	622
Astodrimer sodium added 1-h post-infection	Vero E6	0.019	15.09	794
Astodrimer sodium added 1-h post-infection	Calu-3	0.030	21.76	725
Remdesivir added 1-h post-infection	Vero E6	0.791 μM	N/A	N/A
Remdesivir added 1-h post-infection	Calu-3	0.589 μM	N/A	N/A

EC₅₀ = 50% effective concentration; CC₅₀ = 50% cytotoxic concentration; SI = selectivity index (CC₅₀/EC₅₀); N/A = not applicable.